Answer
The licensed treatment combines the tezacaftor–ivacaftor tablet with a separate ivacaftor tablet to maintain CFTR potentiation as directed by the specialist team.
Sources for this answer
- Symkevi 100 mg/150 mg tablets PLGB 22352/0003emc · SmPC Current selected SmPC · Version 14